All In Biotech

Drug Trial Radar · NCT05203172

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Jul 5, 2022

Primary completion

Jul 31, 2029

Study completion Jun 30, 2032

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jan 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib and/or binimetinib. All participants who took part in earlier encorafenib and/or binimetinib studies may participate in the FLOTILLA study if they are still benefiting from the use of the study medicines. This will be determined by the study doctor. People may not participate in the FLOTILLA study if they were not enrolled in a prior study of encorafenib or binimetinib. Participants who had enrolled but had stopped receiving the study treatment in a prior study cannot be enrolled in this study. Participants in the FLOTILLA study will receive study treatment at the same dose and frequency as in their prior study, for up to about 5 years.

Conditions

  • Solid Tumors

Interventions

  • BinimetinibDrug

    Binimetinib is administered orally twice a day.

  • EncorafenibDrug

    Encorafenib is administered orally once a day.

  • VemurafenibDrug

    Vemurafenib is administered orally twice a day.

  • RibociclibDrug

    Ribociclib is administered orally once a day.

  • CetuximabBiological

    Cetuximab is administered intravenously (IV) every 2 weeks.

  • PembrolizumabBiological

    Pembrolizumab is administered intravenously (IV) every 3 weeks. A maximum of 35 administrations will be given, including doses already given in the Parent Study.

  • NivolumabBiological

    Nivolumab is administered intravenously (IV) every 4 week. A maximum of 24 months of treatment will be given, beginning with the first dose in the Parent Study.

  • 5-FluorouracilDrug

    5-FU is administered intravenously (IV) every 2 weeks.

  • LeucovorinDrug

    Leucovorin is administered intravenously (IV) every 2 weeks. Levo-leucovorin may be given as an alternative for leucovorin.

  • OxaliplatinDrug

    Oxaliplatin is administered intravenously (IV) every 2 or 3 weeks.

  • IrinotecanDrug

    Irinotecan is administered intravenously (IV) every 2 weeks.

  • CapecitabineDrug

    Capecitabine is administered orally twice a day for 14 consecutive days, followed by 7 days off.

  • BevacizumabBiological

    Bevacizumab will be administered intravenously (IV), if applicable.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events leading to permanent discontinuation of study interventionTime frame: Baseline up to approximately 5 years
  2. Number serious adverse events reported for all participantsTime frame: Baseline up to approximately 5 years

Locations

77 sites in 20 countries. Site status is shown where the registry gives one.

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona · Recruiting

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona · Recruiting

  • Emory University Hospital Midtown

    Atlanta, Georgia · Recruiting

  • Emory University Hospital

    Atlanta, Georgia · Recruiting

  • Investigational Drug Service Emory University Clinic

    Atlanta, Georgia · Recruiting

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • HealthPartners Cancer Research Center

    Saint Paul, Minnesota · Recruiting

  • Regions Hospital Pharmacy

    Saint Paul, Minnesota · Recruiting

  • Siteman Cancer Center

    St Louis, Missouri · Recruiting

  • Barnes-Jewish Hospital

    St Louis, Missouri · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • MSK Basking Ridge

    Basking Ridge, New Jersey · Active not recruiting

  • Rockefeller Outpatient Pavilion (53rd Street)

    New York, New York · Active not recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Active not recruiting

  • Duke Cancer Center

    Durham, North Carolina · Recruiting

  • Investigational Chemotherapy Service

    Durham, North Carolina · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Liga Norte Riograndense Contra o Câncer

    Natal, Rio Grande do Norte, Brazil · Recruiting

  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia

    Ijuí, Rio Grande do Sul, Brazil · Recruiting

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil · Not yet recruiting

  • Fundação Pio XII - Hospital de Câncer de Barretos

    Barretos, São Paulo, Brazil · Recruiting

  • BP - A Beneficencia Portuguesa de São Paulo

    São Paulo, São Paulo, Brazil · Recruiting

  • Real e Benemerita Associacao Portuguesa de Beneficencia

    São Paulo, São Paulo, Brazil · Recruiting

  • University Health Network

    Toronto, Ontario, Canada · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • Jewish General Hospital

    Montreal, Quebec, Canada · Recruiting

  • Fakultni nemocnice Olomouc

    Olomouc, Czechia · Recruiting

  • Lekarna Fakultni nemocnice Olomouc

    Olomouc, Czechia · Recruiting

  • Vseobecna fakultni nemocnice v Praze

    Prague, Praha 2, Czechia · Recruiting

  • Hopital Claude Huriez - CHU de Lille

    Lille, NORD, France · Active not recruiting

  • Gustave Roussy

    Villejuif, Val-de-marne, France · Active not recruiting

  • Charité Universitaetsmedizin Berlin - Campus Mitte

    Berlin, Germany · Recruiting

  • Universitaetsklinikum Tuebingen

    Tübingen, Baden-Wurttemberg, Germany · Active not recruiting

  • Otto-von-Guericke-Universitat Magdeburg

    Magdeburg, Saxony-Anhalt, Germany · Active not recruiting

  • General Hospital of Athens ''Laiko''

    Athens, Attikí, Greece · Recruiting

  • General Hospital of Athens "Laiko"

    Athens, Attikí, Greece · Recruiting

  • Debreceni Egyetem Klinikai Kozpont

    Debrecen, Hungary · Recruiting

  • Pécsi Tudományegyetem Klinikai Központ

    Pécs, Baranya, Hungary · Recruiting

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.